PODD250117C100000
- 168.50
- 0.000.00%
Insulet Newsroom
Press Release: Insulet to Announce Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025
Bernstein Adjusts Price Target on Insulet to $315 From $305, Keeps Outperform Rating
Bernstein Maintains Insulet(PODD.US) With Buy Rating, Raises Target Price to $315
Bernstein Maintains Insulet(PODD.US) With Buy Rating, Raises Target Price to $305
Diabetes Device Maker Beta Bionics Files for $100M IPO
Citi Says 'Buy' These Stocks in '25; SA Quant Ratings Says Maybe Not
BofA Securities Maintains Insulet(PODD.US) With Buy Rating, Announces Target Price $305
High Quality Cyclical Stocks According to Morgan Stanley
Express News | Insulet Corp : UBS Raises Target Price to $280 From $253
Wearable Patch Market Report 2025, With Profiles of Key Players Abbott, Medtronic, Dexcom, GlucoWatch, IRhythm Technologies, Insulet, Tactile Medical, VitalConnect, Qardio Myant & BioTelemetry
J.P. Morgan recommends three major gold stocks in Medical Technology for 2025: Boston Scientific, Intuitive Surgical, and Insulet.
JPMorgan selected Boston Scientific and Intuitive Surgical as its preferred Large Cap stocks in the Medical Technology sector in its New Year report, and reaffirmed its favor for the insulin pump manufacturer Insulet in the mid-cap Medical Technology sector.
Here Are J. P. Morgan's Top MedTech Picks for 2025
If You Invested $100 In This Stock 10 Years Ago, You Would Have This Much Today
Insulet Is Maintained at Buy by TD Cowen
TD Cowen Maintains Insulet(PODD.US) With Buy Rating, Maintains Target Price $324
TD Cowen Maintains Insulet(PODD.US) With Buy Rating, Raises Target Price to $324
Express News | Insulet Corp : TD Cowen Raises Target Price to $324 From $264
Insulet Corporation's (NASDAQ:PODD) Share Price Not Quite Adding Up
Looking Into Insulet's Recent Short Interest
BTIG Maintains Insulet(PODD.US) With Buy Rating, Raises Target Price to $300